-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on AbbVie, Raises Price Target to $275

Benzinga·10/09/2026 15:30:02
UBS analyst Michael Yee maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $260 to $275.